首页 >
法规速递
-
Page: Vaccines: concerns, questions and false claims-2026/4/8
2026-04-09查看详情 > -
Document: List of medicinal products under additional monitoring-2026/5/27
2026-05-28查看详情 > -
国家药监局关于发布仿制药参比制剂目录（第六十三批）的通告（2023年第1号）-2023/01/09
2023-01-09查看详情 > -
ICH M7 Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Scientific guideline-2023/7/19
2023-07-21查看详情 > -
Page: Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline-2024/1/26
2024-03-11查看详情 > -
Page: Falsified medicines: overview-2025/1/30
2025-02-05查看详情 > -
Document: Minutes of the CHMP meeting 11-14 November 2024-2025/3/7
2025-03-10查看详情 > -
Document: Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025-2025/4/9
2025-04-11查看详情 > -
Document: Orientation guide for industry - EMA building-2025/5/22
2025-05-23查看详情 > -
Document: Combined VeDDRA list of clinical terms for reporting suspected adverse events in animals and humans to veterinary medicinal products-2025/6/27
2025-06-30查看详情 >
